Sanford Burnham drug slows liver cancer; Yale group points to targeted melanoma drugs;

> Blocking the activity of an immune receptor, the lymphotoxin-beta receptor (LTβR), reduces the progression of liver cancer, according to investigators at Sanford Burnham Prebys Medical Discovery Institute, the National Cancer Institute, and the Chulabhorn Research Institute. Release

> A group at Yale say that a subgroup of genetic mutations present in a number of melanoma skin cancer cases could point to more targeted anti-cancer therapies. Release

> An international team of scientists successfully decoded the genome and transcriptome of an as yet incurable sub-type of acute lymphoblastic leukemia. Release

> Insulin resistance has been linked to lower brain glucose metabolism in a group of late middle-age adults at risk for Alzheimer's disease, according to an article published online by JAMA Neurology. Release